Clinical trial
Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive…
NCT00418132 · NYU Langone Health, Other · Terminated
Key facts
| NCT number | NCT00418132 |
|---|---|
| Title | Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis |
| Official title | T Cell Immunity in Collagen Biosynthesis of Scleroderma |
| Lead sponsor | NYU Langone Health, Other |
| Collaborators | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Scleroderma, Systemic |
| Intervention type | Drug |
| Interventions | Thalidomide, Placebo thalidomide |
| Enrollment | 30 |
| Start date | Aug 1, 2000 |
| Completion | Oct 1, 2007 |
| First posted | Jan 4, 2007 |
| Last update posted | Mar 11, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: